Life Sciences

MaaT Pharma Launches a Global Offering of approximately 18 Million Euros
14 May 2024

MaaT Pharma Launches a Global Offering of approximately 18 Million Euros

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read more
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
8 April 2024

MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read more
Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
15 March 2024

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

The company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's...

Read more
STARFISH Bioscience Raises €900,000 From Seventure Partners To Regenerate Soil Microbiomes By Developing The Next Generation Of Microbial Biostimulants For Sustainable Agriculture
6 February 2024

STARFISH Bioscience Raises €900,000 From Seventure Partners To Regenerate Soil Microbiomes By Developing The Next Generation Of Microbial Biostimulants For Sustainable Agriculture

Starfish Bioscience today announced that it has raised €900,000 from Seventure Partners, the world's leading investor in the microbiome field through its Health for Life...

Read the press release
Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines
5 December 2023

Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines

Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful...

Read more
Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.
26 October 2023

Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.

Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease...

Read the press release
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
26 October 2023

MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013

MaaT Pharma today announced that the DSMB unanimously recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host...

Read more
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
30 June 2023

Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer

Enterome today announces that the first patient was dosed in the Phase 1/2 'AUDREY' trial evaluating EO4010, the Company's third OncoMimics™ candidate, for the treatment of...

Read the press release
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
14 June 2023

Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...

Read the press release